Recent Updates
Recently added Catalysts
UTHR Positive Sentiment

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

Thursday, October 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: United Therapeutics authorized a $2 billion share repurchase program valid through October 21, 2027. The board cited strong free cash flow and balance sheet strength to fund long-term ambitions. Management stated shares currently represent a compelling investment opportunity for the company.

Market Sentiment Analysis

POSITIVE FACTORS

  • Board authorized $2 billion share repurchase program
  • Repurchase program available until October 21, 2027
  • Strong balance sheet supports long-term ambitions
  • Company demonstrates confidence in its stock value

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
5.6%
average across 9 past catalysts
Lead asset
APD811
NDA/BLA · Pulmonary Arterial Hypertension

Full Press Release Details

SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company’s common stock, available through October 21, 2027. “We have the balance sheet and free cash flow to fund our long-term ambitions and the confidence to act decisively when our own shares represent a compelling invest

Frequently Asked Questions

What is the amount of the new share repurchase program?

The new share repurchase program is authorized for up to $2 billion.

Until when is the share repurchase program available?

The program is available through October 21, 2027.

What does this repurchase program indicate about UTHR?

It indicates UTHR's strong balance sheet and confidence in its stock value.

Who authorized the share repurchase program?

The program was authorized by United Therapeutics' Board of Directors.

ShareAdd on Google
Tags: UTHR United Therapeutics share buyback stock repurchase financial news
Last updated: Oct 22, 2026

Biotech snapshot

Cash runway
$3803M liquidity · $0M/mo burn
Low dilution risk
Lead asset
APD811NDA/BLA
Pulmonary Arterial Hypertension →

Catalyst track record

+19%
best trade around UTHR's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for UTHR.

See every catalyst's timing & PoA →